Jaromír Švestka

742 total citations
73 papers, 414 citations indexed

About

Jaromír Švestka is a scholar working on Psychiatry and Mental health, Pharmacology and Pediatrics, Perinatology and Child Health. According to data from OpenAlex, Jaromír Švestka has authored 73 papers receiving a total of 414 indexed citations (citations by other indexed papers that have themselves been cited), including 39 papers in Psychiatry and Mental health, 22 papers in Pharmacology and 6 papers in Pediatrics, Perinatology and Child Health. Recurrent topics in Jaromír Švestka's work include Treatment of Major Depression (22 papers), Schizophrenia research and treatment (20 papers) and Electroconvulsive Therapy Studies (14 papers). Jaromír Švestka is often cited by papers focused on Treatment of Major Depression (22 papers), Schizophrenia research and treatment (20 papers) and Electroconvulsive Therapy Studies (14 papers). Jaromír Švestka collaborates with scholars based in Czechia, Hungary and Poland. Jaromír Švestka's co-authors include Eva Češková, Cyril Höschl, Pavel Mohr, Ján Pečeňák, István Bitter, Tamás Treuer, Norman Sartorius, Marek Jarema, Sergey Mosolov and Ljubomir Hotujac and has published in prestigious journals such as Acta Psychiatrica Scandinavica, European Neuropsychopharmacology and Expert Review of Neurotherapeutics.

In The Last Decade

Jaromír Švestka

61 papers receiving 381 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Jaromír Švestka Czechia	11	290	107	106	52	40	73	414
C.G.G. Link United Kingdom	8	500 1.7×	143 1.3×	79 0.7×	80 1.5×	75 1.9×	14	585
J. Raniwalla United Kingdom	8	393 1.4×	109 1.0×	62 0.6×	84 1.6×	38 0.9×	19	427
S. Heylen Belgium	7	452 1.6×	97 0.9×	94 0.9×	96 1.8×	92 2.3×	11	560
Michael D. Teehan Canada	12	312 1.1×	87 0.8×	119 1.1×	68 1.3×	32 0.8×	22	526
W. Chrzanowski Poland	7	413 1.4×	126 1.2×	96 0.9×	110 2.1×	26 0.7×	11	497
Philippe Bouhours France	11	329 1.1×	131 1.2×	70 0.7×	88 1.7×	63 1.6×	20	481
B.G. Miller United States	7	620 2.1×	123 1.1×	123 1.2×	112 2.2×	67 1.7×	15	720
Nael Kilzieh United States	10	414 1.4×	87 0.8×	168 1.6×	54 1.0×	32 0.8×	16	561
Patrick T. Donlon United States	13	388 1.3×	92 0.9×	150 1.4×	94 1.8×	30 0.8×	31	569
H. A. McClelland United Kingdom	13	300 1.0×	68 0.6×	67 0.6×	60 1.2×	47 1.2×	25	518

Countries citing papers authored by Jaromír Švestka

Since Specialization

Citations

This map shows the geographic impact of Jaromír Švestka's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jaromír Švestka with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jaromír Švestka more than expected).

Fields of papers citing papers by Jaromír Švestka

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jaromír Švestka. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jaromír Švestka. The network helps show where Jaromír Švestka may publish in the future.

Co-authorship network of co-authors of Jaromír Švestka

This figure shows the co-authorship network connecting the top 25 collaborators of Jaromír Švestka. A scholar is included among the top collaborators of Jaromír Švestka based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jaromír Švestka. Jaromír Švestka is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Höschl, Cyril & Jaromír Švestka. (2008). Escitalopram for the treatment of major depression and anxiety disorders. Expert Review of Neurotherapeutics. 8(4). 537–552. 40 indexed citations

Švestka, Jaromír. (2008). Sleep deprivation therapy.. PubMed. 29 Suppl 1. 65–92. 12 indexed citations

Švestka, Jaromír. (2005). Antidepresiva a QT interval. 2(2). 84. 1 indexed citations

Švestka, Jaromír. (2002). Třezalka tečkovaná (Hypericum perforatum linn) - rostlinnéantidepresivum. 6(2). 1 indexed citations

Kasper, Siegfried, Per Bech, Timothy G. Dinan, et al.. (1997). Treatment of unipolar major depression: Algorithms for pharmacotherapy. International Journal of Psychiatry in Clinical Practice. 1(sup1). S5–S7. 4 indexed citations

Švestka, Jaromír, et al.. (1995). [Effectiveness of clonazepam in depressive disorders].. PubMed. 91(4). 199–207. 5 indexed citations

Švestka, Jaromír, et al.. (1992). [The status of fluvoxamine among the antidepressive agents].. PubMed. 88(5). 209–19. 1 indexed citations

Švestka, Jaromír, et al.. (1986). [The effect of oxyprothepine decanoate, lithium and cyproterone acetate on deviant sexual behavior].. PubMed. 82(6). 355–60. 1 indexed citations

Švestka, Jaromír, et al.. (1980). Multicentre Study with Viloxazine (Vivalan®) in DepressedPatients. International Pharmacopsychiatry. 15(4). 228–239. 6 indexed citations

10.

Slama, Borhane, et al.. (1978). Prophylactic lithium treatment of drug abuse.. PubMed. 20(1). 70–2. 2 indexed citations

11.

Švestka, Jaromír, et al.. (1975). Proceedings: The result of lithium therapy in acute phases of affective psychoses and some other prognostical factors of lithium prophylaxis.. PubMed. 17(4). 270–1. 4 indexed citations

12.

Češková, Eva, et al.. (1974). Clinical experience with doxepin.. PubMed. 16(3). 185–6. 2 indexed citations

13.

Švestka, Jaromír, et al.. (1973). Comparison of the short-term therapeutic effect of oxyprothepine and perphenazine in schizophrenic patients. A controlled study.. PubMed. 15(2). 103–4. 4 indexed citations

14.

Švestka, Jaromír, et al.. (1972). A comparison of pimozide with perphenazine in the treatment of acute schizophrenic psychoses.. PubMed. 14(2). 93–4. 10 indexed citations

15.

Švestka, Jaromír, et al.. (1971). To the antidepressive properties of lithium and its place in the group of antidepressive drugs.. PubMed. 13(3). 169–70. 3 indexed citations

16.

Švestka, Jaromír, et al.. (1971). [Experimental and clinical experiences with Encephabol therapy in gerontopsychiatry].. PubMed. 67(3). 129–33. 1 indexed citations

17.

Švestka, Jaromír, et al.. (1971). Comparison of the therapeutic results of clothiapin and perphenazine in schizophrenia.. PubMed. 13(3). 171–171. 2 indexed citations

18.

Švestka, Jaromír, et al.. (1970). [Controlled studies with thiothixene and perphenazine in schizophrenic psychoses].. PubMed. 12(1). 60–1. 1 indexed citations

19.

Švestka, Jaromír, et al.. (1970). Zur Stellung des Lithiums in der Gruppe der Antidepressivain der Behandlung vonakuten endogenen und Involutionsdepressionen. International Pharmacopsychiatry. 5(2-4). 249–257. 7 indexed citations

20.

Švestka, Jaromír, et al.. (1969). [Comparison of the therapeutic effect of triperidol with perphenazine in schizophrenia].. PubMed. 65(5). 281–9. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact